Arzerra Gets a New Boxed WarningLegal ExaminerThe anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab) recently got an upgrade to their boxed warning labels, adding information about the potential risk for reactivation of hepatitis B infectio…
|
Dramatic rise in chemo spending
Oncology Update Just six medicines made up 58% of all chemotherapy costs in 2011: new medications rituximab, imatinib, bevacizumab and trastuzumab, and the older, generic medications docetaxel and paclitaxel. Dr Vitry said it “very surprising” to discover that such a … |
|
Gilead Sciences, Inc. : Gilead’s Idelalisib Significantly Reduces Rate of …
4-traders (press release) (BUSINESS WIRE)–Nov. 18, 2013– Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Phase 3 study (Study 116) evaluating idelalisib in combination with rituximab in previously-treated chronic lymphocytic leukemia (CLL) patients … |
|
Investors Alert: Amgen, Inc. (NASDAQ:AMGN), Galena Biopharma Inc (NASDAQ …
Market News Call 18 announced that the company’s Phase 3 study (Study 116) evaluating idelalisib in combination with rituximab in previously-treated chronic lymphocytic leukemia (CLL) patients who were not fit for chemotherapy was accepted for presentation during a … |
|
Innovations and Developments of Rituximab Biosimilar Market
PR-BG.com (прессъобщения) (press release) November 21,2013 : Bharat Book Bureau presents the new report, on ‘Therapy Class Overview : Rituximab biosimilar’ assesses that Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a … |
Roche Kadcyla OK, drugs cleared as safe after EU probePharmaTimesThe therapies covered by the probe included many of its big-earning cancer drugs such as MabThera/Rituxan (rituximab), Herceptin (trastuzumab), Avastin (bevacizumab) and Tarceva (erlotini…
|
Remission reinduction with rituximab a possibility for ANCA-associated vasculitis
Skin and Allergy News Digital Network SAN DIEGO – Retreatment of granulomatosis with polyangiitis or microscopic polyangiitis with rituximab may be safe and effective in reinducing remission, a prospective trial has shown. “The vast majority of patients with ANCA [antineutrophil … |
|
Janssen Oncology Data to be Presented at 2013 American Society of …
Business Wire (press release) Combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP): updated results from a phase 1b study in treatment-naïve patients with CD20-positive B-cell non-Hodgkin’s lymphoma (NHL). (Abstract 852). |
Medscape |
Burkitt’s Yields to Longer-Duration, Lower-Dose Chemo
Medscape For 19 adults with sporadic Burkitt’s lymphoma, a dose-adjusted version of the EPOCH-R (etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and rituximab) regimen was associated with 95% progression-free survival and 100% overall … Low-intensity therapy very effective in Burkitt lymphomaOncology Nurse Advisor |
NierNieuws.nl |
‘Patiënten met Hepatitis B niet behandelen met rituximab‘
NierNieuws.nl Alle patiënten moeten voor de start van een behandeling met rituximab (MabThera) gescreend worden op het hepatitis B-virus (HBV). Patiënten met een actieve hepatitis B-infectie dienen niet behandeld te worden met rituximab. Aanbevolen wordt ook om … |